LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 4 of 15: Mean cell count and mean growth rate across biological replicate 1. - Dataset (ID:20240)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | PD0325901 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 3192 | 5505 | 0.5798 | 0.3988 |
BT-20 | PD0325901 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 3157 | 5505 | 0.5734 | 0.3896 |
BT-20 | PD173074 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 5503 | 5505 | 0.9996 | 0.9994 |
BT-20 | PD184352 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 2987 | 5505 | 0.5426 | 0.3455 |
BT-20 | Pelitinib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 1202 | 5505 | 0.2184 | -0.1183 |
BT-20 | PF431396 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 1706 | 5505 | 0.3099 | 0.0125 |
BT-20 | PF477736 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 2114 | 5505 | 0.3840 | 0.1186 |
BT-20 | PF562271 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 1301 | 5505 | 0.2364 | -0.0925 |
BT-20 | PHA-665752 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 4059 | 5505 | 0.7372 | 0.6240 |
BT-20 | PHA-793887 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 1369 | 5505 | 0.2488 | -0.0749 |
BT-20 | PI103 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 1434 | 5505 | 0.2605 | -0.0581 |
BT-20 | PLX-4720 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 2924 | 5505 | 0.5311 | 0.3291 |
BT-20 | QL-X-138 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 1231 | 5505 | 0.2237 | -0.1108 |
BT-20 | QL-XII-47 | 10.0 | uM | LJP6 | 72 | hr | 1657 | 799 | 5505 | 0.1452 | -0.2231 |
BT-20 | Radicicol | 10.0 | uM | LJP5 | 72 | hr | 1657 | 1506 | 5505 | 0.2737 | -0.0393 |
BT-20 | Radicicol | 10.0 | uM | LJP6 | 72 | hr | 1657 | 1525 | 5505 | 0.2770 | -0.0345 |
BT-20 | Seliciclib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 2184 | 5505 | 0.3967 | 0.1369 |
BT-20 | Ruxolitinib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 3984 | 5505 | 0.7237 | 0.6047 |
BT-20 | XL147 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 2185 | 5505 | 0.3969 | 0.1370 |
BT-20 | Saracatinib | 10.0 | uM | LJP6 | 72 | hr | 1657 | 2213 | 5505 | 0.4020 | 0.1443 |
BT-20 | Selumetinib | 10.0 | uM | LJP6 | 72 | hr | 1657 | 5417 | 5505 | 0.9840 | 0.9770 |
BT-20 | Sirolimus | 10.0 | uM | LJP6 | 72 | hr | 1657 | 3799 | 5505 | 0.6900 | 0.5565 |
BT-20 | Sorafenib | 10.0 | uM | LJP6 | 72 | hr | 1657 | 2825 | 5505 | 0.5132 | 0.3034 |
BT-20 | SU11274 | 10.0 | uM | LJP5 | 72 | hr | 1657 | 2093 | 5505 | 0.3803 | 0.1133 |
BT-20 | Fedratinib | 10.0 | uM | LJP5 | 72 | hr | 1657 | 1702 | 5505 | 0.3091 | 0.0115 |